Bottle Label 5 mg (71610 0324 08)
Tadalafil
Product Images NDC 71610-324
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-324). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Bottle Label 20 mg (71610 0325 04)
Aphena Pharma Solutions (TN)
Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)
Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)
This is a table showing the results of a study that compares the effects of taking Tadalafil 20mg and doxazosin 8mg versus a placebo and doxazosin 8mg on standing and supine systolic blood pressure at different time points after the dose.*
Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)
This appears to be a chart or table related to a medical study. It shows the effect of different treatments on systolic blood pressure (measured in mmHg) at different times after administration of tadalafil or placebo. The treatments tested were either a combination of 20 mg tadalafil and 8 mg doxazosin (taken at either 8:00 or 20:00) or doxazosin alone with placebo. The description does not provide information on the purpose of the study or the context in which the data were collected.*
Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)
Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)
The text describes the change in IPSS total score and the duration of treatment in weeks between Tadalafil 5 mg and Placebo, indicating a statistically significant difference with p<0.01. Therefore, it is a useful description of the comparison between the two treatments for this particular outcome.*
Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)
This is a graph showing the change in International Prostate Symptom Score (IPSS) total score over a 12-week treatment duration for tadalafil 5 mg and placebo. The results show a significant improvement in IPSS total score for tadalafil 5 mg compared to placebo (p<0.01).*
Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)
The text provides information about the "Change from Baseline in IPSS Total Score" for the duration of the treatment in weeks, comparing the effects of Tadalafil 5 mg versus Placebo. It also indicates a significant difference between the two groups with p<0.01.*
Spl-tadalafil-structure (Spl Tadalafil Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
